((tetrahydro-2H-pyran-4-yl)methyl)zinc(II) bromide | 1012041-98-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: ((tetrahydro-2H-pyran-4-yl)methyl)zinc(II) bromide
• 英文别名: [(tetrahydro-2H-pyran-4-yl)methyl]zinc(II) bromide
• CAS: 1012041-98-3
• 化学式: C₆H₁₁BrOZn
• 分子量: 244.447
• InChiKey: QMLREUVTJBBGKK-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  9.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.23
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  ((tetrahydro-2H-pyran-4-yl)methyl)zinc(II) bromide 、 5-bromo-3-((1-ethyl-1H-pyrazol-5-yl)oxy)picolinamide 在 2-双环己基膦-2',6'-二甲氧基联苯 、 palladium diacetate 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 6.75h， 生成 1-(3-((1-ethyl-1H-pyrazol-5-yl)oxy)-5-((tetrahydro-2H-pyran-4-yl)methyl)pyridin-2-yl)-3-methylurea
  参考文献：
  名称：

  C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators

  摘要：

  Glucokinase (GK) activators represent a class of type 2 diabetes therapeutics actively pursued due to the central role that GK plays in regulating glucose homeostasis. Herein we report a novel C5-alkyl-2-methylurea-substituted pyridine series of GK activators derived from our previously reported thiazolylamino pyridine series. Our efforts in optimizing potency, enzyme kinetic properties, and metabolic stability led to the identification of compound 26 (AM-9514). This analogue showed a favorable combination of in vitro potency, enzyme kinetic properties, acceptable pharmacokinetic profiles in preclinical species, and robust efficacy in a rodent PD model.

  DOI：

  10.1021/ml500341w
• 作为产物：
  描述：

  4-溴甲基四氢吡喃 在 碘 、 锌 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 12.0h， 生成 ((tetrahydro-2H-pyran-4-yl)methyl)zinc(II) bromide
  参考文献：
  名称：

  [EN] HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
  [FR] COMPOSÉS HÉTÉROARYLE UTILES EN TANT QU'INHIBITEURS DE L'ENZYME D'ACTIVATION SUMO

  摘要：

  公开了公式(I)的化合物或其药物可接受的盐； 其中Y、Ra、Ra'、Rb、Rc、X1、X2、X3、Rd、Z1和Z2具有本文所述的值，并且星号位置表示的立体化学配置指示绝对立体化学。 根据本公开的化学实体可用作Sumo激活酶（SAE）的抑制剂。 进一步提供了包含本公开化合物的药物组合物以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或病症的方法。

  公开号：

  WO2016004136A1

文献信息

• Nickel-Catalyzed Alkyl-Alkyl Cross-Couplings of Fluorinated Secondary Electrophiles: A General Approach to the Synthesis of Compounds having a Perfluoroalkyl Substituent
  作者：Yufan Liang、Gregory C. Fu

  DOI：10.1002/anie.201503297

  日期：2015.7.27

  to a tertiary carbon atom by using an alkyl–alkyl cross‐coupling. A nickel catalyst derived from NiCl2⋅glyme and a pybox ligand achieves the coupling of a wide range of fluorinated alkyl halides with alkylzinc reagents at room temperature. A broad array of functional groups is compatible with the reaction conditions, and highly selective couplings can be achieved on the basis of differing levels of

  氟化有机分子在药物化学到聚合物科学等领域都令人感兴趣。本文描述的是一种温和，方便且通用的方法，该方法通过使用烷基-烷基交叉偶联来合成带有连接至叔碳原子的全氟烷基的化合物。源自NiCl 2的镍催化剂乙二醇和pybox配体可在室温下实现多种氟化烷基卤与烷基锌试剂的偶联。各种各样的官能团与反应条件相容，并且基于不同的氟化水平可以实现高度选择性的偶联。机理研究表明，在这些条件下2,2,6,6-四甲基-1-哌啶基氧基（TEMPO）的存在会抑制交叉偶联，并且可以分离出TEMPO-亲电子加合物。
• [EN] UREA COMPOUNDS AS GKA ACTIVATORS<br/>[FR] COMPOSÉS D'URÉE EN TANT QU'ACTIVATEURS DE LA GKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2013086397A1

  公开（公告）日：2013-06-13

  The present invention relates to compounds, to pharmaceutical compositions comprising the compounds, to a process for making the compounds and to the use of the compounds in therapy. More particularly, it relates to certain glucokinase activators of Formulas 1 and 1a, useful in the treatment of diseases and disorders that would benefit from activation of glucokinase.

  本发明涉及化合物，包括含有该化合物的药物组合物，制备该化合物的方法以及在治疗中使用该化合物。更具体地，涉及到某些葡萄糖激酶激活剂的1和1a式，可用于治疗需要激活葡萄糖激酶的疾病和障碍。
• HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160009744A1

  公开（公告）日：2016-01-14

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R a , R a′ , R b , R c , X 1 , X 2 , X 3 , R d , Z 1 , and Z 2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  本发明涉及化学实体，其为以下式（I）的化合物或其药学上可接受的盐；其中，Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1和Z2具有本文所述的值，并在星号位置描绘的立体化学构型表示绝对立体化学。根据本发明的化学实体可用作Sumo激活酶（SAE）的抑制剂。进一步提供了包括本发明化合物的制药组合物以及使用这些组合物治疗增生性、炎症性、心血管和神经退行性疾病或疾患的方法。
• Heteroaryl compounds useful as inhibitors of sumo activating enzyme
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US10335410B2

  公开（公告）日：2019-07-02

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  所公开的化学实体为式（I）化合物： 或其药学上可接受的盐；其中 Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1 和 Z2 具有本文所述的值，星号位置描述的立体化学构型表示绝对立体化学。根据本公开的化学实体可用作苏木活化酶（SAE）的抑制剂。进一步提供了包含本公开化合物的药物组合物，以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或紊乱的方法。
• Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US10780090B2

  公开（公告）日：2020-09-22

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  所公开的化学实体为式（I）化合物： 或其药学上可接受的盐；其中 Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1 和 Z2 具有本文所述的值，星号位置描述的立体化学构型表示绝对立体化学。根据本公开的化学实体可用作苏木活化酶（SAE）的抑制剂。进一步提供了包含本公开化合物的药物组合物，以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或紊乱的方法。